Aytu BioPharma (NASDAQ:AYTU) Price Target Raised to $14.50

Aytu BioPharma (NASDAQ:AYTU) had its price target lifted by analysts at Ascendiant Capital Markets from $14.00 to $14.50 in a report released on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Several other equities analysts have also commented on AYTU. Zacks Research raised shares of Aytu BioPharma from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aytu BioPharma in a report on Wednesday, April 8th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $9.83.

Aytu BioPharma Price Performance

AYTU stock opened at $2.24 on Thursday. The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 0.27. Aytu BioPharma has a 12 month low of $1.65 and a 12 month high of $3.07. The firm has a market cap of $24.04 million, a P/E ratio of -0.49 and a beta of 0.24. The company’s 50-day moving average price is $2.41 and its two-hundred day moving average price is $2.45.

Aytu BioPharma (NASDAQ:AYTU) last released its earnings results on Wednesday, May 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.09). Aytu BioPharma had a negative net margin of 60.17% and a negative return on equity of 69.93%. The firm had revenue of $12.41 million during the quarter, compared to the consensus estimate of $12.05 million. On average, analysts anticipate that Aytu BioPharma will post -0.69 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aytu BioPharma

A number of hedge funds have recently made changes to their positions in the stock. Diadema Partners LP boosted its stake in shares of Aytu BioPharma by 12.1% in the 4th quarter. Diadema Partners LP now owns 305,788 shares of the company’s stock valued at $795,000 after purchasing an additional 33,118 shares in the last quarter. Persistent Asset Partners Ltd boosted its stake in shares of Aytu BioPharma by 27.2% in the 4th quarter. Persistent Asset Partners Ltd now owns 79,415 shares of the company’s stock valued at $206,000 after purchasing an additional 16,963 shares in the last quarter. Two Sigma Investments LP boosted its stake in shares of Aytu BioPharma by 96.2% in the 3rd quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock valued at $129,000 after purchasing an additional 33,701 shares in the last quarter. Arete Wealth Advisors LLC acquired a new stake in shares of Aytu BioPharma in the 1st quarter valued at approximately $135,000. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Aytu BioPharma by 23.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 43,585 shares of the company’s stock valued at $119,000 after purchasing an additional 8,222 shares in the last quarter. 33.49% of the stock is currently owned by institutional investors and hedge funds.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.